Preferred Label : avelumab;
MeSH hyponym : MSB0010682; MSB-0010718C;
UNII : KXG2PJ551I;
Origin ID : C000609138;
UMLS CUI : C4055417;
ATC code(s)
- Currated CISMeF NLP mapping
- Manual BTNT mappings - CISMeF
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3470393/fr/bavencio-avelumab-carcinome-a-cellules-de-merkel
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
Antineoplastic Agents, Immunological
avelumab
evaluation of the transparency committee
carcinoma, merkel cell
avelumab
---
https://ansm.sante.fr/tableau-marr/avelumab
2022
false
false
false
France
French
immune system diseases
avelumab
avelumab
Drug-Related side effects and adverse reactions
Infusion related reaction
signs and symptoms
patient education handout
infusions, intravenous
avelumab
risk management
immune system diseases
antineoplastic agents
antineoplastic agents
Drug-Related side effects and adverse reactions
immune system diseases
guidelines for drug use
patients guideline
antibodies, monoclonal
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3243896/fr/bavencio-carcinome-urothelial-avelumab
2021
France
evaluation of the transparency committee
avelumab
avelumab
Carcinoma
carcinoma
---
https://www.has-sante.fr/jcms/p_3243896/fr/bavencio-carcinome-urothelial
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
avelumab
avelumab
infusions, intravenous
Antineoplastic Agents, Immunological
adult
neoplasm metastasis
Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
urologic neoplasms
carcinoma
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3165896/fr/bavencio
2020
false
false
false
France
treatment outcome
avelumab
infusions, intravenous
antineoplastic agents
avelumab
insurance, health, reimbursement
adult
neoplasm metastasis
carcinoma, merkel cell
evaluation of the transparency committee
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3184665/fr/bavencio-rein
2020
false
false
false
France
avelumab
avelumab
antineoplastic combined chemotherapy protocols
Axitinib
antineoplastic agents
insurance, health, reimbursement
treatment outcome
clear cell renal cell carcinoma
Avelumab/Axitinib Regimen
prognosis
survival analysis
Avelumab/Axitinib Regimen
evaluation of the transparency committee
carcinoma, renal cell
antibodies, monoclonal
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00385
2018
false
false
false
Canada
French
English
drug information
avelumab
avelumab
antibodies, monoclonal
---
https://www.has-sante.fr/portail/jcms/c_2872662/fr/bavencio
2018
false
false
false
France
French
avelumab
avelumab
treatment outcome
orphan drug production
adult
Antineoplastic Agents, Immunological
carcinoma, merkel cell
infusions, intravenous
B7-H1 Antigen
neoplasm metastasis
evaluation of the transparency committee
survival analysis
antibodies, monoclonal
---
https://www.ema.europa.eu/medicines/human/EPAR/Bavencio
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
avelumab
avelumab
avelumab
drug monitoring
product surveillance, postmarketing
treatment outcome
orphan drug production
adult
antineoplastic agents
antineoplastic agents
carcinoma, merkel cell
infusions, intravenous
B7-H1 Antigen
neoplasm metastasis
pregnancy
breast feeding
IgG1
drug evaluation, preclinical
immunoglobulin G
antibodies, monoclonal
antibodies, monoclonal
---
